S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride crystalline salt

Abstract

A novel mixed salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is disclosed. The novel mixed salt, S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, may be produced to form crystals that may be arranged as generally orderly packed agglomerates, which are particularly useful in making pharmaceutical compositions. Such pharmaceutical compositions are also described, as well as methods to make crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, and methods of treating conditions characterized by an overexpression on nitric oxide from the inducible isoform of nitric oxide synthase using the S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.

1 . A crystalline form of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride characterized by at least one of: x-ray powder pattern substantially as shown in  FIG. 1 ; a loss of mass of about 1 percent over a range of temperature of about forty degrees Celsius to about one-hundred eighty degrees Celsius; Raman spectrum substantially as shown in  FIG. 5 ; and elemental analysis substantially as in Table 1.  
     
     
         2 . The crystalline form of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride of  claim 1  wherein a plurality of crystals are amassed as agglomerates.  
     
     
         3 . The crystalline form of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride agglomerates of  claim 2  wherein said plurality of crystals are amassed as generally orderly packed agglomerates.  
     
     
         4 . A pharmaceutical composition comprising the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride of  claim 1  together with a pharmaceutically acceptable carrier.  
     
     
         5 . A method of treating a condition wherein pathologically high production forms a part in a subject in need of such treatment comprising administering to the subject an effective amount of the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride of  claim 1 .  
     
     
         6 . A method of making the generally orderly packed agglomerate crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride of  claim 3  utilizing a crystallization procedure comprising adding an anti-solvent to a solvent solution in which is dissolved S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, thereby forming a system comprising two phases, and precipitating generally orderly packed agglomerate crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.  
     
     
         7 . The method of  claim 6  wherein the anti-solvent solution is added to the solvent solution in which is dissolved S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, followed by addition of seed crystals to the system.  
     
     
         8 . The method of  claim 6  wherein the anti-solvent comprises acetone.  
     
     
         9 . The method of  claim 6  wherein the solvent solution comprises 1-butanol and S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.  
     
     
         10 . The method of  claim 6  wherein the anti-solvent comprises acetonitrile, and the solvent solution comprises N,N-dimethylformamide and S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.  
     
     
         11 . The method of  claim 6  wherein the anti-solvent comprises acetone, and the solvent solution comprises 1-butanol and S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.  
     
     
         12 . The method of  claim 7  wherein no less than about one percent by weight of the total S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride in the system is introduced as added seed crystals.  
     
     
         13 . The method of  claim 6  wherein a sufficient amount of anti-solvent is added to a solvent solution comprising S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride in a reaction vessel to form a reaction system, until one of a) turbidity or b) an oily coating on a surface of said reaction vessel is visually apparent, and adding seed crystals to said system.  
     
     
         14 . The method of  claim 7  wherein the seed crystals are created in-situ by at least one of: 
 reducing the water content of the solvent solution; reducing the amount of maleic acid; or    altering the rate of super-saturation generation.    
     
     
         15 . The method of  claim 6  wherein no seed crystals are added to the system, and the ratio of anti-solvent added to the system exceeds the ratio of solvent solution in which is dissolved S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride by about one hundred and ten percent by weight that of the ratio of anti-solvent to solvent used in a system wherein seed crystals are added, to precipitate generally orderly packed agglomerate crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.